Greenwich LifeSciences Inc. has announced the ongoing global expansion of their Phase III FLAMINGO-01 trial, focusing on GLSI-100, a novel breast cancer vaccine immunotherapy. This trial is now active at over 120 sites across the United States and Europe. GLSI-100 combines the HER2-derived GP2 peptide with GM-CSF and aims to prevent breast cancer recurrences. In a prior Phase II trial, promising results were observed, showing no metastatic recurrences in immunized patients. The company has outlined a strategy to accelerate commercialization of GLSI-100, emphasizing advanced manufacturing readiness and strong academic partnerships. Results from the Phase III trial have not yet been presented.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。